Diagnosis and management of hyponatremia in cancer patients

Oncologist

Volumn 17, Issue 6, 2012, Pages 756-765

  Castillo, Jorge J ^a   Vincent, Marc ^b   Justice, Eric ^c  

^a BROWN UNIVERSITY   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c BioScience Communications   (United States)

Author keywords

Arginine vasopressin; Cancer; Hyponatremia; Syndrome of inappropriate antidiuretic hormone; Tolvaptan

Indexed keywords

ARGIPRESSIN; ARGIPRESSIN RECEPTOR; CONIVAPTAN; DEMECLOCYCLINE; LITHIUM; MOZAVAPTAN; PLACEBO; POTASSIUM; SODIUM; SODIUM CHLORIDE; TOLVAPTAN; UREA; URIC ACID; VASOPRESSIN;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CONTINUOUS INFUSION; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; EXTRACELLULAR SPACE; FLUID THERAPY; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY; HYPERVOLEMIA; HYPONATREMIA; HYPOTHYROIDISM; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY CARCINOMA; LIVER FAILURE; LUNG SMALL CELL CANCER; MICTURITION DISORDER; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PLASMA OSMOLALITY; PRIORITY JOURNAL; SIDE EFFECT; SODIUM BLOOD LEVEL; THIRST; UREA NITROGEN BLOOD LEVEL; UREMIA; URINE OSMOLALITY; XEROSTOMIA;

ARGININE VASOPRESSIN; BENZAZEPINES; DISEASE MANAGEMENT; HUMANS; HYPONATREMIA; HYPOVOLEMIA; INAPPROPRIATE ADH SYNDROME; NEOPLASMS; RECEPTORS, VASOPRESSIN; RISK FACTORS; SODIUM;

EID: 84862846656     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0400     Document Type: Article

References (61)

1. Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother 2003;37: 1694-1702.
2. Onitilo AA, Kio E, Doi SA. Tumor-related hyponatremia. Clin Med Res 2007;5:228-237.
3. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342:1581-1589.
4. Lassen U, Østerlind K, Hansen M et al. Long-term survival in small-cell lung cancer: Posttreatment characteristics in patients surviving 5 to 18_ years-an analysis of 1,714 consecutive patients. J Clin Oncol 1995;13: 1215-1220.
5. Østerlind K, Andersen PK. Prognostic factors in small cell lung cancer: Multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986;46:4189-4194.
6. Allan SG, Stewart ME, Love S et al. Prognosis at presentation of small cell carcinoma of the lung. Eur J Cancer 1990;26:703-705.
7. Hansen O, Srensen P, Hansen KH. The occurrence of hyponatremia in SCLC and the influence on prognosis: A retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer 2010;68: 111-114.
8. Harper PG, Souhami RL, Spiro SG et al. Tumor size, response rate, and prognosis in small cell carcinoma of the bronchus treated with combination chemotherapy. Cancer Treat Rep 1982;66:463-470.
9. Gross AJ, Steinberg SM, Reilly JG et al. Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium. Cancer Res 1993; 53:67-74.
10. Raftopoulos H. Diagnosis and management of hyponatremia in cancer patients. Support Care Cancer 2007;15:1341-1347.
11. Souhami RL, Bradbury I, Geddes DM et al. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 1985;45:2878-2882.
12. Cerny T, Blair V, Anderson H et al. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 1987;39:146-149.
13. Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990;61:597-604.
14. Kawahara M, Fukuoka M, Saijo N et al. Prognostic factors and prognostic staging system for small cell lung cancer. Jpn J Clin Oncol 1997;27:158-165.
15. Maestu I, Pastor M, Gómez-Codina J et al. Pretreatment prognostic factors for survival in small-cell lung cancer: A new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol 1997;8:547-553.
16. Ray P, Quantin X, Grenìer J et al. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. Cancer Detect Prev 1998;22:293-304.
17. Mohan A, Goyal A, Singh P et al. Survival in small cell lung cancer in India: Prognostic utility of clinical features, laboratory parameters and response to treatment. Indian J Cancer 2006;43:67-74.
18. Kimura T, Kudoh S, Hirata K et al. Prognostic factors in elderly patients with unresectable non-small cell lung cancer. Anticancer Res 2001;21:1379-1383.
19. Jacot W, Colinet B, Bertrand D et al.; OncoLR Health Network. Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients. Ann Oncol 2008;19:1458-1464.
20. Vasudev NS, Brown JE, Brown SR et al. Prognostic factors in renal cell carcinoma: Association of preoperative sodium concentration with survival. Clin Cancer Res 2008;14:1775-1781.
21. Jeppesen AN, Jensen HK, Donskov F et al. Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br J Cancer 2010;102:867-872.
22. Kim HS, Yi SY, Jun HJ et al. Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology 2007;73:192-197.
23. Aggerholm-Pedersen N, Rasmussen P, Dybdahl H et al. Serum natrium determines outcome of treatment of advanced GIST with imatinib: A retrospective study of 80 patients from a single institution. ISRN Oncol 2011; 2011:523915.
24. Dhaliwal HS, Rohatiner AZ, Gregory W et al. Combination therapy for intermediate and high grade non-Hodgkin's lymphoma. Br J Cancer 1993;68:767-774.
25. Hampshire PA, Welch CA, McCrossan LA et al. Admission factors associated with hospital mortality in patients with haematological malignancy admitted to UK adult, general critical care units: A secondary analysis of the ICNARC Case Mix Programme Database. Crit Care 2009;13:R137.
26. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009;122:857-865.
27. Doshi SM, Shah P, Lei X et al. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis 2012;59:222-228.
28. Verbalis JG, Goldsmith SR, Greenberg A et al. Hyponatremia treatment guidelines 2007: Expert panel recommendations. Am J Med 2007;120(suppl 1):S1-S21.
29. Schrier RW. Vasopressin and aquaporin 2 in clinical disorders of water homeostasis. Semin Nephrol 2008;28:289-296.
30. Johnson BE, Chute JP, Rushin J et al. Aprospective study of patients with lung cancer and hyponatremia of malignancy. Am J Respir Crit Care Med 1997;156: 1669-1678.
31. Chute JP, Taylor E, Williams J et al. A metabolic study of patients with lung cancer and hyponatremia of malignancy. Clin Cancer Res 2006;12:888-896.
32. List AF, Hainsworth JD, Davis BW et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol 1986; 4:1191-1198.
33. Sørensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 1995;238: 97-110.
34. Talmi YP, Hoffman HT, McCabe BF. Syndrome of inappropriate secretion of arginine vasopressin in patients with cancer of the head and neck. Ann Otol Rhinol Laryngol 1992;101:946-949.
35. Ferlito A, Rinaldo A, Devaney KO. Syndrome of inappropriate antidiuretic hormone secretion associated with head and neck cancers: Review of the literature. Ann Otol Rhinol Laryngol 1997;106:878-883.
36. Robertson GL, Bhoopalam N, Zelkowitz LJ. Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone. Arch Intern Med 1973;132:717-720.
37. Stuart MJ, Cuaso C, Miller M et al. Syndrome of recurrent increased secretion of antidiuretic hormone following multiple doses of vincristine. Blood 1975;45: 315-320.
38. Liamis G, Milionis H, Elisaf M. A review of druginduced hyponatremia. Am J Kidney Dis 2008;52:144-153.
39. Harlow PJ, DeClerck YA, Shore NA et al. A fatal case of inappropriate ADH secretion induced by cyclophosphamide therapy. Cancer 1979;44:896-898.
40. Bressler RB, Huston DP. Water intoxication following moderate-dose intravenous cyclophosphamide. Arch Intern Med 1985;145:548-549.
41. Hamdi T, Latta S, Jallad B et al. Cisplatin-induced renal salt wasting syndrome. South Med J 2010;103: 793-799.
42. Momi J, Tang CM, Abcar AC et al. Hyponatremia-what is cerebral salt wasting? Permanente J 2010; 14:62-65.
43. Sterns RH, Silver SM. Brain volume regulation in response to hypo-osmolality and its correction. Am J Med 2006;119(suppl 1):S12-S16.
44. Adrogué HJ. Consequences of inadequate management of hyponatremia. AmJ Nephrol 2005;25:240-249.
45. Douglas I. Hyponatremia: Why it matters, how it presents, how we can manage it. Clev Clin J Med 2006; 73(suppl 3):S4-S12.
46. Zenenberg RD, Carluccio AL, Merlin MA. Hyponatremia: Evaluation and management. Hosp Pract (Minneap) 2010;38:89-96.
47. Rose BD, ed. Hyponatremia and hyperkalemia in adrenal insufficiency. In: Clinical Physiology of Acid-Base and Electrolyte Disorders, Fourth Edition. New York: McGraw-Hill, 1994:672-675.
48. Graber M, Corish D. The electrolytes in hyponatremia. Am J Kidney Dis 1991;18:527-545.
49. Rachoin JS, Cerceo EA. Four nephrology myths debunked. J Hosp Med 2011;6:E1-E5.
50. Sherlock M, Thompson CJ. The syndrome of inap-propriate antidiuretic hormone: Current and future management options. Eur J Endocrinol 2010;162(suppl 1): S13-S18.
51. Verbalis JG. AVP receptor antagonists as aquaretics: Review and assessment of clinical data. Cleve Clin J Med 2006;73(suppl 3):S24-S33.
52. Yamaguchi K, Shijubo N, Kodama T et al.; Ectopic ADH Syndrome Therapeutic Research Group. Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome. Jpn J Clin Oncol 2011;41:148-152.
53. Ghali JK, Farah JO, Daifallah S et al. Conivaptan and its role in the treatment of hyponatremia. Drug Des Devel Ther 2009;3:253-268.
54. Samsca (tolvaptan) tablets for oral use [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical, Inc., 2009.
55. Yamamura Y, Nakamura S, Itoh S et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998;287:860-867.
56. Costello-Boerrigter LC, Smith WB, BoerrigterGet al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006;290:F273-F278.
57. 2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-2112.
58. Verbalis JG, Adler S, Schrier RW et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 2011;164:725-732.
59. Cárdenas A, Ginès P, Marotta P et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol 2012;56:571-578.
60. Samsca (tolvaptan) Tablets (2009) Annex I. Summary of Product Characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/000980/ WC500048716.pdf, accessed June 14, 2011.
61. Berl T, Quittnat-Pelletier F, Verbalis JG et al.; SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010;21:705-712.